Intravitreal Aflibercept Injection for Radiation Retinopathy

Radiation retinopathy can cause decreased vision in patients who have received either
external beam radiation or local plaque therapy to the eye. An early manifestation of
radiation retinopathy is macular edema, which represents fluid within the retina that affects
central vision. There is currently no approved treatment for this disease, although there
have been anecdotal reports of benefit with laser photocoagulation, intravitreal anti-VEGF
agents, or intravitreal steroid use. This is a phase 1 study to evaluate aflibercept for the
treatment of macular edema associated with retinopathy secondary to previous radiation
treatment.

Inclusion Criteria:

- Retinopathy associated with previous I-125 brachytherapy for uveal melanoma (85 Gy
over 96 hours) at least 6 months prior to enrollment

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study

- Age > 18 years

- Center involved macular edema > 300µm in thickness on SD-OCT

- Best corrected visual acuity of 20/40- 20/400

- Birth control therapy for females of child-bearing age

Exclusion Criteria:

- Pre-existing retinopathy due to other disorders

- Vision decrease is considered to be due to ischemic radiation retinopathy without
macular edema or optic neuropathy

- Presence of metastasis

- Pregnancy (positive pregnancy test) or lactation

- Premenopausal women not using adequate contraception. The following are considered
effective means of contraception: surgical sterilization or use of oral
contraceptives, barrier contraception with either a condom or diaphragm in conjunction
with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

- Prior enrollment in any study with intravitreal aflibercept injection

- Any other condition that the investigator believes would pose a significant hazard to
the subject if the investigational therapy were initiated

- Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment
with anti-glaucoma medication)

- History of cerebral vascular accident, myocardial infarction, transient ischemic
attacks within 4 months of study enrollment.

- Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
eye

- Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic
retinopathy) that, in the opinion of the investigator, could either require medical or
surgical intervention during the study period to prevent or treat visual loss that
might result from that condition, or if allowed to progress untreated, could likely
contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 6-month
study period

- Presence of significant subfoveal fibrosis or atrophy

- Intraocular surgery (including cataract surgery) in the study eye within 2 months of
enrollment

- Active intraocular inflammation (grade trace or above) in the study eye

- History of allergy to fluorescein, ICG or iodine, not amenable to treatment

- Prior/Concomitant Treatment:

- Panretinal photocoagulation treatment

- Previous intraocular steroids or PDT within 3 months

- Previous participation in any studies of investigational drugs within 30 days
preceding Day 0 (excluding vitamins and minerals)

- Previous treatment with intravitreally (in either eye) or intravenously administered
Avastin (bevacizumab) within 60 days or concomitant use in either eye outside the
scope of this study

- Previous use of Eylea, Macugen or Lucentis in study eye within 60 days or concomitant
use in either eye outside the scope of this study

- Prior submacular or vitreous surgery